Acquisition Announced
Novartis acquisition of Myricx Bio
US$1.1bn consideration
Announced 6 Jul 2026
Advisers
Novartis
Acquirer
Not disclosed
- Target
- Myricx Bio
- Acquirer
- Novartis
- Seller
- Brandon Capital Partners
- Target based in
- United Kingdom
- Buyer based in
- Switzerland
- Sector
- Biotech
- Tags
- Biotech, Oncology
Similar deals
- J&J acquisition of FireFly Biologics 2026 · US$1bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
Sources
- 6 Jul 2026 Brandon Capital announces agreement for Novartis to acquire portfolio company Myricx Bio brandoncapital.vc
- 6 Jul 2026 Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology goodwinlaw.com
- 6 Jul 2026 Press release (GlobeNewswire), Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform globenewswire.com
- 7 Jul 2026 Brandon Capital scores its biggest return ever with $2.1b deal forbes.com.au
- 7 Sep 2026 Brandon Capital: Myricx Bio acquisition by Novartis deal closes brandoncapital.vc
